# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Ma

Applicant:

Suzanne Klimberg et al.

IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

Docket No.:

781.020US1

Serial No.: 10/633,402

Filed:

August 1, 2003

Examiner:

Kevin E. Weddington

Group Art Unit: 1614

## Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

 $\underline{X}$  Return postcard.

- X Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), and copies of 10 cited documents.
- $\underline{X}$  Check in the amount of \$180.00 to cover the fee for consideration of Information Disclosure Statement under 97(c).

Please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

By: Warren D. Woessner

Reg. No. 30,440

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this \_\_\_\_\_\_\_\_ day of May, 2006.\_\_\_\_

\_\_\_\_\_

Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)

<u>S/N 10/633,402</u> <u>PATENT</u>

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicant:

V. Suzanne Klimberg et al.

Examiner:

Kevin E. Weddington

erial No.:

10/633,402

Group Art Unit:

1614

Filed:

August 01, 2003

Docket:

781.020US1

Title:

IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants have included the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

05/23/2006 SFELEKE1 00000002 10633402

01 FC:1806

180.00 OP

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :10/633,402

Filing Date: August 01, 2003

Title: IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted, V. SUZANNE KLIMBERG ET AL.

By their Representatives, SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938 Minneapolis, MN 55402 (612) 373-6903

Date 5-17-06

Warren D. Woessner

Reg. No. 30,440

NICOLC JACK

Signature

PTO/S8/084(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Tretement Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE 10/633,402 **Application Number** STATEMENT BY APPLICATE August 1, 2003 (Use as many sheets as necessary) **Filing Date** MAX 2 2 2006 Klimberg, V. **First Named Inventor** 1614 **Group Art Unit** Weddington, Kevin **Examiner Name** Attorney Docket No: 781.020US1 Sheet 1 of 1

US PATENT DOCUMENTS							
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate			
<del></del>	US-5,932,235	08/03/1999	Ninomiya, Hiroshi, et al.	06/23/1998			
	US-6,102,254	08/15/2000	Ross, M.	02/17/1999			
	US-7,041,651	05/09/2006	Petit, II, R. G., et al.	03/09/2004			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T²			
·	JP-06-192108	07/12/1994	Satoshi, Y., et al.				
	JP-07-010743	01/13/1995	Frank, R. M.				
	JP-09-187233	07/22/1997	Hiroshi, N., et al.				
	JP-10-511637	11/10/1998					
	JP-62-169730	07/25/1987	Zonmaamaiyaa, K., et al.	-			
	JP-62-283927	12/09/1987	Benjiyamin, E. J., et al.				
	WO-9608238A1	03/21/1996	Bye, A., et al.				
	WO-9706813A1	02/27/1997	Yamamoto, N., et al.				
	WO-9843643A1	10/08/1998	Kusumoto, M., et al.				

	OTH	ER DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		BOZZETTI, F., et al., "Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study", Nutrition, 13(7-8), (July-Aug., 1997), 748-751	